Causes and consequences of interpersonal microbial variation
人际微生物变异的原因和后果
基本信息
- 批准号:9294121
- 负责人:
- 金额:$ 4.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-06-10 至 2021-05-31
- 项目状态:已结题
- 来源:
- 关键词:AminosalicylateAnaerobic BacteriaAnimalsBacteriaCommunitiesDataEnzymesGastrointestinal tract structureGenomicsGnotobioticGoalsHealthHumanIn VitroIndividualMeasuresMedicalMetabolismMicrobeMusPatientsPharmaceutical PreparationsResearchShapesTestingUlcerative ColitisVariantdrug metabolismepidemiological modelexperimental studygut microbiomeimprovedinsightmicrobialmicrobial communitymicrobiomemicrobiotamouse modelprogramspublic health relevanceresponsesmall molecule
项目摘要
DESCRIPTION (provided by applicant): Individuals vary widely in drug response. Microbes in the human gastrointestinal tract influence drug metabolism at multiple levels, but we cannot currently predict whether an individual's gut microbial community (microbiota) predisposes them towards efficient or inefficient metabolism of almost any drug. The long-term goals of this research program are to understand the mechanisms that create interpersonal variation in human gut microbial communities and to measure how this variation impacts drug metabolism. We describe experiments that will uncover how three general mechanisms (direct bacterial interaction, small molecule exchange, and host modulation of the microbiota) determine microbiome dynamics. First, wildtype and genetically manipulated human gut symbionts will be studied in vitro and in gnotobiotic mouse models. Next, genomic analyses and epidemiological modeling will be used to connect experimental results from genetically tractable human gut anaerobes to the entire microbiome. Defined assemblies of human gut microbes will then be examined in vitro and in gnotobiotic mice in order to test predictions from the experimental and computational data. In parallel, we will also apply these approaches to dissect the consequences of microbiome variation on metabolism of 5-aminosalicylate (5-ASA), a front-line drug for ulcerative colitis that is directly modified by bacterial enzymes. This proposal presents plan to integrate drug responsiveness results from patients initiating or currently taking 5-ASA with in vitro and gnotobiotic animal studies of 5-ASA metabolism by their microbiomes. Together, these studies will provide key mechanistic insights critical for adding or removing species in human gut microbiomes in a predictable and stable manner; for manipulating individuals' microbiomes in order to improve medical therapy, and for measuring the contribution of the microbiome to individual drug responses.
描述(由申请人提供):药物反应的个体差异很大。人类胃肠道中的微生物在多个层面上影响药物代谢,但我们目前无法预测一个人的肠道微生物群落(微生物区系)是否使他们倾向于几乎任何药物的高效或低效代谢。这项研究计划的长期目标是了解在人类肠道微生物群落中造成人际差异的机制,并测量这种差异如何影响药物代谢。我们描述了将揭示三种一般机制(直接细菌相互作用、小分子交换和微生物区系的宿主调制)如何决定微生物组动态的实验。首先,野生型和基因操纵的人类肠道共生体将在体外和灵知生菌小鼠模型中进行研究。下一步,将使用基因组分析和流行病学建模来将从遗传上易受影响的人类肠道厌氧菌的实验结果与整个微生物组联系起来。然后,将在体外和灵知生菌小鼠身上检查确定的人类肠道微生物集合,以检验从实验和计算数据中做出的预测。同时,我们还将应用这些方法来剖析微生物群变化对5-氨基水杨酸盐(5-ASA)代谢的影响,5-ASA是一种治疗溃疡性结肠炎的一线药物,直接由细菌酶修饰。这项建议提出了一项计划,将患者开始或目前服用5-ASA的药物反应结果与他们的微生物群对5-ASA代谢的体外和生理学动物研究相结合。总之,这些研究将提供关键的机制见解,这些见解对于以可预测和稳定的方式添加或移除人类肠道微生物群中的物种至关重要;对于操纵个人的微生物群以改进医学治疗,以及衡量微生物群对个人药物反应的贡献至关重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew L Goodman其他文献
Andrew L Goodman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew L Goodman', 18)}}的其他基金
Understanding the contributions of microbiome-encoded drug metabolizing enzymes
了解微生物组编码的药物代谢酶的贡献
- 批准号:
10626934 - 财政年份:2019
- 资助金额:
$ 4.69万 - 项目类别:
Understanding the contributions of microbiome-encoded drug metabolizing enzymes
了解微生物组编码的药物代谢酶的贡献
- 批准号:
10018636 - 财政年份:2019
- 资助金额:
$ 4.69万 - 项目类别:
Understanding the contributions of microbiome-encoded drug metabolizing enzymes
了解微生物组编码的药物代谢酶的贡献
- 批准号:
10461800 - 财政年份:2019
- 资助金额:
$ 4.69万 - 项目类别:
Understanding the contributions of microbiome-encoded drug metabolizing enzymes
了解微生物组编码的药物代谢酶的贡献
- 批准号:
9817111 - 财政年份:2019
- 资助金额:
$ 4.69万 - 项目类别:
Causes and consequences of interpersonal microbial variation
人际微生物变异的原因和后果
- 批准号:
10798726 - 财政年份:2016
- 资助金额:
$ 4.69万 - 项目类别:
Causes and consequences of interpersonal microbial variation
人际微生物变异的原因和后果
- 批准号:
10621815 - 财政年份:2016
- 资助金额:
$ 4.69万 - 项目类别:
Causes and consequences of interpersonal microbial variation
人际微生物变异的原因和后果
- 批准号:
10388949 - 财政年份:2016
- 资助金额:
$ 4.69万 - 项目类别:
Causes and consequences of interpersonal microbial variation
人际微生物变异的原因和后果
- 批准号:
10406968 - 财政年份:2016
- 资助金额:
$ 4.69万 - 项目类别:
Causes and consequences of interpersonal microbial variation
人际微生物变异的原因和后果
- 批准号:
9071690 - 财政年份:2016
- 资助金额:
$ 4.69万 - 项目类别:
Causes and consequences of interpersonal microbial variation
人际微生物变异的原因和后果
- 批准号:
10204342 - 财政年份:2016
- 资助金额:
$ 4.69万 - 项目类别:
相似海外基金
Identification and isolation of anaerobic bacteria that degrade bacterial cell wall
降解细菌细胞壁的厌氧菌的鉴定与分离
- 批准号:
22H02487 - 财政年份:2022
- 资助金额:
$ 4.69万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Enzymology of cofactor and amino acid metabolism in anaerobic bacteria
厌氧菌辅助因子和氨基酸代谢的酶学
- 批准号:
RGPIN-2022-03200 - 财政年份:2022
- 资助金额:
$ 4.69万 - 项目类别:
Discovery Grants Program - Individual
Elucidating the mechanisms of O2-sensitivity of anaerobic bacteria Bifidobacterium.
阐明厌氧菌双歧杆菌的 O2 敏感性机制。
- 批准号:
22K07058 - 财政年份:2022
- 资助金额:
$ 4.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
High-throughput isolation of anaerobic bacteria
厌氧菌的高通量分离
- 批准号:
572711-2022 - 财政年份:2022
- 资助金额:
$ 4.69万 - 项目类别:
University Undergraduate Student Research Awards
Automatic and accurate identification of aerobic bacteria, anaerobic bacteria, yeasts, and fungi in clinical samples derived from animals and from feed for pets
自动、准确地鉴定来自动物和宠物饲料的临床样品中的需氧细菌、厌氧细菌、酵母菌和真菌
- 批准号:
10440741 - 财政年份:2021
- 资助金额:
$ 4.69万 - 项目类别:
Regulation of virulence in fungi under coculture condition with anaerobic bacteria
厌氧菌共培养条件下真菌毒力的调节
- 批准号:
21K07009 - 财政年份:2021
- 资助金额:
$ 4.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Polymicrobial interactions between commensal obligate anaerobic bacteria and cystic fibrosis pathogen P. aeruginosa
共生专性厌氧菌与囊性纤维化病原体铜绿假单胞菌之间的多种微生物相互作用
- 批准号:
10275319 - 财政年份:2021
- 资助金额:
$ 4.69万 - 项目类别:
Platform for the automated isolation and characterization of anaerobic bacteria
厌氧菌自动分离和表征平台
- 批准号:
445552570 - 财政年份:2020
- 资助金额:
$ 4.69万 - 项目类别:
Major Research Instrumentation
Development of therapy for triple negative breast cancer using anaerobic bacteria
利用厌氧菌开发三阴性乳腺癌疗法
- 批准号:
19K16452 - 财政年份:2019
- 资助金额:
$ 4.69万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of gene engineering method for anaerobic bacteria for efficient bio-hydrogen production
开发厌氧菌高效生物制氢的基因工程方法
- 批准号:
18K11708 - 财政年份:2018
- 资助金额:
$ 4.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)